Avenzo Therapeutics Honored by Goldman Sachs for Entrepreneurship
16 10월 2024 - 9:30PM
Business Wire
Athena Countouriotis, M.D., Co-founder,
President and CEO Among the Most Exceptional Entrepreneurs at 2024
Builders and Innovators Summit
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage
biotechnology company developing the next generation of oncology
therapeutics, today announced that Goldman Sachs (NYSE:GS) is
recognizing Athena Countouriotis, M.D., Co-founder, President and
CEO of Avenzo, as one of the Most Exceptional Entrepreneurs of 2024
at its Builders and Innovators Summit in Healdsburg,
California.
Goldman Sachs selected Dr. Countouriotis from multiple
industries to be honored at the two-day event. Dr. Countouriotis
co-founded Avenzo in 2022 after leading Turning Point Therapeutics
as President and Chief Executive Officer through its IPO in 2019 to
its eventual acquisition by Bristol Myers Squibb for $4.1 billion
in August 2022. With over 20 years of industry experience, she has
served as an officer in both public and private companies, led
multiple initial public offerings and acquisitions, and guided
several development programs to approval in the U.S. and
Europe.
“It is a great honor to be recognized by Goldman Sachs among
such a distinguished group of entrepreneurs,” said Athena
Countouriotis, M.D., Co-founder, President and CEO of Avenzo
Therapeutics. “This recognition is a reflection of the commitment
and tireless efforts of our team at Avenzo, as we work to advance
our pipeline of next-generation oncology therapies to potentially
transform cancer treatment for patients.”
“I am thrilled to recognize Athena Countouriotis, M.D. as one of
the most exceptional entrepreneurs of 2024,” said David Solomon,
Chairman and CEO of Goldman Sachs. “Athena and her team have built
an impressive business that continues to grow at scale. We look
forward to bringing this year’s cohort together to share insights
on topics ranging from the evolving geopolitical landscape and
accessing new pools of capital to using the power of storytelling
to reach new audiences.”
In its 13th year, Goldman’s Builders and Innovators Summit is
the can’t miss gathering for Founders and CEOs of high growth
companies. Previous honorees have gone on to lead multi-billion
dollar companies, both in the private and public markets. In
addition to honoring the most exceptional entrepreneurs each year,
the Summit consists of general sessions and clinics led by seasoned
entrepreneurs, academics and business leaders as well as resident
scholars.
About Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage biotechnology company
focused on developing the next generation of oncology therapies for
patients. The company’s lead drug candidate, AVZO-021, is a novel,
highly potent and selective inhibitor of CDK2, a key enzyme
involved in cell cycle regulation. AVZO-021 is being studied in a
Phase 1 study in the U.S. for the treatment of advanced solid
tumors and in combinations in HR+/HER2-negative metastatic breast
cancer. Avenzo is headquartered in San Diego, California. For more
information, visit us at www.avenzotx.com or on LinkedIn.
About Goldman Sachs
Goldman Sachs is a leading global financial institution that
delivers a broad range of financial services to a large and
diversified client base that includes corporations, financial
institutions, governments and individuals. Founded in 1869, the
firm is headquartered in New York and maintains offices in all
major financial centers around the world.
Press related questions about the Summit or Goldman Sachs,
please contact Sophia Anthony at Sophia.Anthony@gs.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241016251966/en/
Carla Taub Media Relations ctaub@avenzotx.com Sophia Anthony
Sophia.Anthony@gs.com.
Goldman Sachs (NYSE:GS)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 10월(10) 2024
Goldman Sachs (NYSE:GS)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024